Journal article
Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries
Benjamin A Rogers, Paul R Ingram, Naomi Runnegar, Matthew C Pitman, Joshua T Freeman, Eugene Athan, Sally M Havers, Hanna E Sidjabat, Mark Jones, Earleen Gunning, Mary De Almeida, Kaylene Styles, David L Paterson
Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2014
DOI: 10.1128/AAC.02052-13
Abstract
By global standards, the prevalence of community-onset expanded-spectrum-cephalosporin-resistant (ESC-R) Escherichia coli remains low in Australia and New Zealand. Of concern, our countries are in a unique position, with high extramural resistance pressure from close population and trade links to Asia-Pacific neighbors with high ESC-R E. coli rates. We aimed to characterize the risks and dynamics of community-onset ESC-R E. coli infection in our low-prevalence region. A case-control methodology was used. Patients with ESC-R E. coli or ESC-susceptible E. coli isolated from blood or urine were recruited at six geographically dispersed tertiary care hospitals in Australia and New Zealand. Epide..
View full abstractGrants
Funding Acknowledgements
The laboratory component of this work was supported by a grant from The Royal Brisbane and Womens Hospital Foundation. The use of the Diversilab for this study was supported by bioMerieux (Australia), who supplied consumables for the Diversilab at a discounted cost. B. A. R. is funded by an Australian Postgraduate Award Scholarship. D. L. P. has received honoraria from AstraZeneca, Merck, and Pfizer. P. R. I., N.R., M. C. P., J.T.F., E. A., S. M. H., H. E. S., M.J., E. G., M. D. A., and K. S. received no funding.